Fragrance avoidance
Not a strong fit for fragrance avoidance because it carries Fragrance.
The ingredient itself is a fragrance-linked signal, so it is better treated as an avoid case when fragrance exposure is the main concern.
Potassium or sodium hydroxide is restricted in cosmetic products under Annex III of the EU Cosmetics Regulation (EC) 1223/2009.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 70/100 (high) · high confidence.
Regional restrictions
Prevalence of SODIUM HYDROXIDE in our catalog (epa_cpdat).
Products
11,688
Brands
6
Typical roles
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
Not a strong fit for fragrance avoidance because it carries Fragrance.
The ingredient itself is a fragrance-linked signal, so it is better treated as an avoid case when fragrance exposure is the main concern.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
EU
EC
Annex III of EU Cosmetics Regulation (EC) 1223/2009: substances which cosmetic products must not contain except subject to the restrictions laid down. Product types: (a) Nail cuticle solvent (b) Hair straightener (c) pH adjuster for depilatories (d) Other uses as pH adjuster Callosity softener/remover (entry 15d) Maximum concentration: (a) 5% (b) 2% (General use) and 4.5% (Professional use) Entry 15d: 1,5% Other conditions: (b) 1. General use 2. Professional use (c) up to pH 12.7 (d) up to pH 11 15 d Contains alcakali, Avoid contact with eyes Keep out of reach of chindren ans Read directions for use carefully Conditions of use and warnings: (a) Contains alkali Avoid contact with eyes Can cause blindness Keep out of reach of children (b) 1. Contains alkali Avoid contact with eyes Can cause blindness Keep out of reach of children 2. For professional use only Avoid contact with eyes Can cause blindness (c) Keep out of reach of children Avoid contact with eyes
US
EPA
EPA CPDat observed this chemical in 11688 composition records across product categories including Construction and building materials, Raw materials, Home maintenance. EPA CPDat classifies this chemical for functional uses including pH regulating agent, pH balancer, alkalinizing agent.
Champoings
Pantene
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: ADJ PH
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION/ DROPS; Potency: ADJ PH
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED; Potency: 0.08 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED PELLETS; Potency: 0.01 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Potency: 0.25 mg
US
FDA
Route: AURICULAR (OTIC); Dosage form: SOLUTION; Potency: 0.8 %w/w
US
FDA
Route: AURICULAR (OTIC); Dosage form: SOLUTION/ DROPS; Potency: ADJ PH
US
FDA
Route: AURICULAR (OTIC); Dosage form: SUSPENSION; Potency: ADJ PH
US
FDA
Route: AURICULAR (OTIC); Dosage form: SUSPENSION/ DROPS; Potency: ADJ PH
US
FDA
Route: BUCCAL; Dosage form: FILM, SOLUBLE; Maximum daily exposure: 5 mg
US
FDA
Route: BUCCAL; Dosage form: MOUTHWASH; Potency: 2 mg/1ml
US
FDA
Route: DENTAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: ENDOTRACHEAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: ENDOTRACHEAL; Dosage form: POWDER, FOR SUSPENSION; Potency: ADJ PH
US
FDA
Route: ENDOTRACHEAL; Dosage form: SUSPENSION; Potency: ADJ PH
US
FDA
Route: EPIDURAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: EPIDURAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: EPIDURAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: EXTRACORPOREAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INFILTRATION; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INFILTRATION; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTERSTITIAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRA-AMNIOTIC; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTERIAL; Dosage form: INJECTION; Potency: 176 mg
US
FDA
Route: INTRA-ARTERIAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTERIAL; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTERIAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTERIAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRA-ARTICULAR; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: ADJ PH
US
FDA
Route: INTRABURSAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRACARDIAC; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRACAUDAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRACAUDAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRACAVERNOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRACAVITARY; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRACAVITARY; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRADERMAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRADERMAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRADERMAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: ADJ PH
US
FDA
Route: INTRADISCAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRALESIONAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 176 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 7.01 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 0.35 %w/v
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 78 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 27 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: LIQUID; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: 5.4 mg
US
FDA
Route: INTRAOCULAR; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAPERITONEAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRAPERITONEAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAPLEURAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRASPINAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRASYNOVIAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRASYNOVIAL; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRASYNOVIAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: ADJ PH
US
FDA
Route: INTRATHECAL; Dosage form: INJECTION; Potency: 176 mg
US
FDA
Route: INTRATHECAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRATHECAL; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRATHECAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRATHECAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRATUMOR; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRATUMOR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAVASCULAR; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRAVASCULAR; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAVASCULAR; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTABLE, LIPOSOMAL; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 456 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, EMULSION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 136.55 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 78.36 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 78 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SUSPENSION, LIPOSOMAL; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: LIQUID; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: POWDER; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: SOLUTION; Potency: 2.78 %w/v
US
FDA
Route: INTRAVENOUS; Dosage form: SOLUTION, CONCENTRATE; Potency: ADJ PH
US
FDA
Route: INTRAVESICAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: IONTOPHORESIS; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: IRRIGATION; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: NASAL; Dosage form: SPRAY, METERED; Potency: ADJ PH
US
FDA
Route: OPHTHALMIC; Dosage form: EMULSION; Potency: 0.02 %w/v
US
FDA
Route: OPHTHALMIC; Dosage form: GEL; Maximum daily exposure: 6 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, LIQUID FILLED; Potency: 1.5 mg
US
FDA
Route: ORAL; Dosage form: CONCENTRATE; Potency: 10 mg/5ml
US
FDA
Route: ORAL; Dosage form: FILM, SOLUBLE; Maximum daily exposure: 11 mg
US
FDA
Route: ORAL; Dosage form: GRANULE, FOR SUSPENSION; Potency: ADJ PH
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Maximum daily exposure: 9 mg
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 9120 mg
US
FDA
Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 10 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 4 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 13 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 8 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 1 mg
US
FDA
Route: PARENTERAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: PARENTERAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: PARENTERAL; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: PARENTERAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: PERIDURAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: PERINEURAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: PERIODONTAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: RECTAL; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: AEROSOL, METERED; Potency: ADJ PH
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: POWDER; Potency: ADJ PH
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: SOLUTION; Potency: 8 %w/v
US
FDA
Route: RETROBULBAR; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SOFT TISSUE; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SOFT TISSUE; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: SUBARACHNOID; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: SUBCONJUNCTIVAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION; Potency: 31.45 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SOLUTION; Potency: 1 %w/v
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SUSPENSION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: SUSPENSION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: NA
US
FDA
Route: SUBMUCOSAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SUBMUCOSAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: AEROSOL, FOAM; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 69 mg
US
FDA
Route: TOPICAL; Dosage form: CREAM, AUGMENTED; Maximum daily exposure: 6 mg
US
FDA
Route: TOPICAL; Dosage form: EMULSION; Potency: 0.2 %w/w
US
FDA
Route: TOPICAL; Dosage form: GEL; Maximum daily exposure: 20 mg
US
FDA
Route: TOPICAL; Dosage form: LOTION; Maximum daily exposure: 21 mg
US
FDA
Route: TOPICAL; Dosage form: LOTION, AUGMENTED; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: OINTMENT; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: OINTMENT, AUGMENTED; Potency: 0.11 %w/w
US
FDA
Route: TOPICAL; Dosage form: SHAMPOO; Maximum daily exposure: 3 mg
US
FDA
Route: TOPICAL; Dosage form: SOLUTION; Maximum daily exposure: 39 mg
US
FDA
Route: TOPICAL; Dosage form: SOLUTION/ DROPS; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: SUSPENSION/ DROPS; Potency: ADJ PH
US
FDA
Route: TRANSDERMAL; Dosage form: FILM, EXTENDED RELEASE; Potency: 0.85 mg
US
FDA
Route: TRANSDERMAL; Dosage form: GEL; Maximum daily exposure: 350 mg
US
FDA
Route: TRANSDERMAL; Dosage form: GEL, METERED; Maximum daily exposure: 350 mg
US
FDA
Route: URETERAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: URETHRAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: VAGINAL; Dosage form: CREAM; Potency: 0.19 %w/w
US
FDA
Route: VAGINAL; Dosage form: GEL; Maximum daily exposure: 20 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION; Potency: 0.05 %w/v
US
FDA
openFDA substance registry classifies this ingredient as chemical.
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Potency: ADJ PH